Best Zepbound providers compared in 2026

The August 2026 Zepbound label names the product

Zepbound is Lilly's tirzepatide injection. The label revised August 2026 says it is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

The same label says coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. An offer that says tirzepatide, GLP-1, or weight management, and does not name Zepbound, has not identified this product. The catalog that follows is limited to published Zepbound offers from commission-earning providers.

Mounjaro and compounded tirzepatide are separate products

Mounjaro's label, also revised August 2026, indicates it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. A Mounjaro price belongs in the Mounjaro comparison.

FDA's page, content current as of 1 October 2026, says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness, or quality before marketing. The 1 April 2026 compounding update describes section 503A conditions, including an identified-patient prescription and the restriction on regularly compounding essentially copies of a commercially available drug. This guide does not decide whether a particular compounded offer meets those conditions. Compounded tirzepatide prices stay on the compounded tirzepatide program page, where the product name is on the row.

A compounded tirzepatide price and a Mounjaro price are not Zepbound prices. The Zepbound catalog excludes both.

Continuing terms the Zepbound catalog can show

The methodology checked on 15 October 2026 stores the introductory price, the continuing monthly price, the upfront charge, the prepaid effective monthly price, the commitment length, and medication inclusion separately. The Zepbound rows below rank a medication-included continuing price when the offer publishes one. A prepaid offer shows the effective monthly rate and the amount paid up front. A separate care fee, when the offer publishes one, appears on the basis line.

A provider is listed when its visit link can earn a commission and the Zepbound offer has a published price, a check date, and a source. Programs with no public price are omitted from the ranked rows. The directory is the tracked commission-earning set.

• Does the written offer name Zepbound?
• Does the published price include the medication?
• Is the figure the continuing price, a prepaid effective rate, or an introductory month?
• Which consultation, membership, laboratory, or shipping charge does the same offer require?
• What do the current terms say about renewal, cancellation, a decision not to prescribe, and eligibility in the reader's state?

Checks that stay outside this catalog

A reader's insurance benefit, the clinician's decision to prescribe, and the states a program currently serves are not facts on the Zepbound label and are not filled in from another customer's experience. An in-network clinician and a covered Zepbound benefit are separate insurer questions. Payment for an enrollment visit does not, on the sources checked here, establish that a prescription will be written.

Manufacturer self-pay terms for vials and the KwikPen are a different price record from a telehealth service fee. Those manufacturer figures live on the Zepbound cost guide, with the date they were checked. This page does not copy them into a provider ranking.